Sanofi (NASDAQ:SNY) Stock Rating Lowered by StockNews.com

Sanofi (NASDAQ:SNY) was downgraded by stock analysts at StockNews.com from a “buy” rating to a “hold” rating in a research note issued on Friday.

Separately, Citigroup upgraded shares of Sanofi to a “strong-buy” rating in a research note on Tuesday, September 17th. Two analysts have rated the stock with a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $57.50.

Sanofi Stock Performance

SNY opened at $48.46 on Friday. The stock has a market cap of $122.98 billion, a P/E ratio of 24.72, a P/E/G ratio of 1.22 and a beta of 0.58. Sanofi has a 1 year low of $45.22 and a 1 year high of $58.97. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65. The firm has a fifty day moving average price of $51.90 and a 200 day moving average price of $52.09.

Sanofi (NASDAQ:SNY) last released its earnings results on Friday, October 25th. The company reported $1.57 earnings per share for the quarter, topping analysts’ consensus estimates of $0.22 by $1.35. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. The firm had revenue of $13.44 billion for the quarter, compared to analyst estimates of $16.59 billion. During the same period in the prior year, the firm earned $2.55 earnings per share. The business’s quarterly revenue was up 12.3% compared to the same quarter last year. Equities research analysts anticipate that Sanofi will post 4.28 earnings per share for the current year.

Hedge Funds Weigh In On Sanofi

Institutional investors and hedge funds have recently made changes to their positions in the stock. Tidal Investments LLC acquired a new stake in shares of Sanofi in the 1st quarter worth approximately $228,000. Mather Group LLC. grew its holdings in shares of Sanofi by 451.8% in the 2nd quarter. Mather Group LLC. now owns 1,948 shares of the company’s stock worth $95,000 after acquiring an additional 1,595 shares during the period. Lantz Financial LLC grew its holdings in shares of Sanofi by 23.2% in the 2nd quarter. Lantz Financial LLC now owns 8,054 shares of the company’s stock worth $391,000 after acquiring an additional 1,518 shares during the period. QRG Capital Management Inc. grew its holdings in shares of Sanofi by 4.2% in the 2nd quarter. QRG Capital Management Inc. now owns 140,161 shares of the company’s stock worth $6,801,000 after acquiring an additional 5,641 shares during the period. Finally, Hexagon Capital Partners LLC grew its holdings in shares of Sanofi by 5.5% in the 2nd quarter. Hexagon Capital Partners LLC now owns 5,101 shares of the company’s stock worth $248,000 after acquiring an additional 267 shares during the period. 10.04% of the stock is owned by institutional investors and hedge funds.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.